Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antabio novel target small molecule program
- Development stage
- Unknown
- Lead developer
- Antabio
- Modality
- Small Molecules
01
Overview
Antabio is advancing several discovery-stage programs focused on identifying small molecule inhibitors against novel, undisclosed bacterial targets to combat antimicrobial resistance (AMR). These initiatives include a partnership with the Global Antibiotic Research and Development Partnership (GARDP) to develop new chemical series for high-priority resistant pathogens. By targeting biological pathways distinct from those addressed by current antibiotics, these programs aim to provide new therapeutic options for infections where existing treatments are failing. As these candidates are in the discovery phase, specific chemical structures and precise mechanisms of action remain proprietary.
- Other names
- Antabio novel target AMR program
02
Targets
LasB (Pseudomonas aeruginosa elastase)MBL (Class B metallo-beta-lactamase)
Beyond the preview
Go deeper on Antabio novel target small molecule program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antabio novel target small molecule program.